Company / Accounts Receivable
Avidity Biosciences, Inc. Accounts Receivable History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
-
FY2024
5-year range
$0 / $2.4M
FY2022-FY2024
Trend
-100.0%
vs FY2023
Sector context
#114 of 113
Health Care
What the data says
Declined from $2M to $0 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom -1% in Health CareTop 101% of 113
▼
Key checks
Key Insights
- In FY2024, accounts receivable decreased 100.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $1.1M | -53.3% |
| FY2022 | $2.4M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026